Patents Assigned to Glialogix, Inc.
  • Publication number: 20200009118
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine and an ABCG2 inhibitor.
    Type: Application
    Filed: February 7, 2019
    Publication date: January 9, 2020
    Applicant: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark W. Moore, David K. Lyon, Casey K. Jager, Doug Lorenz, Corey Bloom, Kimberley Shepard
  • Patent number: 10398713
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: September 3, 2019
    Assignee: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Publication number: 20190015431
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Application
    Filed: April 17, 2018
    Publication date: January 17, 2019
    Applicant: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Patent number: 9980978
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: May 29, 2018
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Patent number: 9974798
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: May 22, 2018
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Publication number: 20180110760
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine and an ABCG2 inhibitor.
    Type: Application
    Filed: October 20, 2017
    Publication date: April 26, 2018
    Applicant: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark W. Moore, David K. Lyon, Casey K. Jager, Doug Lorenz, Corey Bloom, Kimberly Shepard
  • Patent number: 9918997
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: March 20, 2018
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Patent number: 9597339
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 21, 2017
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Publication number: 20140221321
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 7, 2014
    Applicant: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon